阳普医疗(300030) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥158,563,957.54, a decrease of 11.69% compared to the same period last year[4] - Net profit attributable to shareholders was ¥13,633,861.49, representing a significant increase of 136.16% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥12,559,469.71, up 132.23% from the previous year[4] - The basic earnings per share improved to ¥0.04, compared to a loss of ¥0.12 in the same quarter last year, marking a 133.33% increase[4] - The company reported a significant increase in operating profit to ¥15,762,432.61, up 144.53% year-on-year[12] - Total operating revenue for Q1 2023 was ¥158,563,957.54, a decrease of 11.7% compared to ¥179,558,042.65 in Q1 2022[30] - Net profit for Q1 2023 reached ¥1,728,803.13, compared to a net loss of ¥37,314,648.73 in Q1 2022, marking a significant turnaround[30] - The company reported an operating profit of ¥15,762,432.61 in Q1 2023, compared to an operating loss of ¥35,397,536.95 in the same period last year[30] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,575,685,333.65, reflecting a 1.12% increase from the end of the previous year[4] - The company’s total liabilities increased to ¥740,902,549.11 from ¥737,568,558.82 year-over-year[30] - The total equity attributable to shareholders of the parent company rose to ¥797,984,297.23, up from ¥784,349,030.45 in the previous year[30] Cash Flow - The cash flow from operating activities showed a slight improvement, with a net outflow of ¥17,982,500.06, a 7.92% reduction in outflow compared to the previous year[4] - The net cash flow from investment activities was ¥15,812,418.98, a turnaround of 144.63% compared to the previous period[14] - The net cash flow from operating activities for Q1 2023 was -¥17,982,500.06, compared to -¥19,528,640.89 in Q1 2022, indicating a slight improvement[35] - The company reported a total cash outflow from operating activities of ¥203,456,313.74 in Q1 2023, down from ¥232,021,366.27 in Q1 2022, indicating improved cash management[35] - The company’s cash flow management strategies appear to be improving, as evidenced by the reduced net cash outflow from operating activities year-over-year[35] Investment and Financing - Investment income for the quarter was ¥10,528,707.60, a turnaround from a loss of ¥39,719,251.68 in the same period last year, representing a 126.51% increase[12] - The company received tax refunds of ¥2,263,481.06, an increase of 31.64% compared to the previous period[14] - Investment income received amounted to ¥19,973,330.11, a significant increase of 9052.46% due to dividends from Shenzhen Yanghe[14] - Short-term bank loans increased by 43.58%, with cash received from borrowings totaling ¥153,500,000.00[14] - The company paid out ¥4,623,453.81 in dividends and interest, an increase of 36.79% due to higher bank loan interest payments[14] - Cash inflow from financing activities increased to ¥153,507,700.00 in Q1 2023, up from ¥106,910,000.00 in Q1 2022, leading to a net cash flow from financing activities of ¥28,881,444.39, compared to ¥8,578,653.52 in the previous year[35] Market and Product Development - The company is actively expanding its market presence internationally, engaging with distributors and end-users in the Middle East, Europe, Africa, and West Asia[23] - The company launched the "Return to Simplicity - Needle-Free Venous Blood Collection Design Competition" to promote innovative and safer medical products[21] - The company participated in the 2023 Arab International Medical Laboratory Instruments and Equipment Exhibition, showcasing its vacuum blood collection system and smart laboratory solutions[23] - The company is committed to enhancing its core technology research and development capabilities, aiming for continuous innovation and improved product value[19] - The company's main products, "disposable vacuum blood collection tubes" and "thromboelastography instruments," were recognized as "2022 Guangdong Province Excellent High-tech Products" by the Guangdong Provincial High-tech Enterprise Association[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,840[15] - The top shareholder, Deng Guanhua, holds 15.91% of shares, totaling 49,194,555 shares, with 38,466,416 shares pledged[15] - The company has a total of 40,777,333 restricted shares at the beginning of the period, with 2,240,631 shares released during the period[18]